To collect post marketing surveillance data on consecutive patients with peripheral arterial occlusive disease (PAOD) intended to be or treated by the VITUS peripheral drug-coated dilatation catheter when used according to the Instructions for Use and treating physician decision. Data will be collected in order to assess the long-term safety and performance of the VITUS peripheral drug-coated dilatation catheter in routine clinical practice.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of participants with Adjudicated freedom from major adverse events (MAE)
Timeframe: 30 days post-procedure (primary safety endpoint at 30 days)
Proportion of participants with Adjudicated freedom from major adverse events (MAE)
Timeframe: 12 months post-procedure (primary safety and efficacy endpoint at 12 months)
Occurrence of Adjudicated freedom from cd-TLR
Timeframe: 12 months post-procedure (primary efficacy endpoint at 12 months)